Skip to Content

CK16-02a

Main Content

Contemporary role of maintenance tyrosine kinase inhibitors following allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: A CIBMTR analysis.

Study #: CK16-02a

Study Status: Published

Presentation(s)

2018, EBMT (Oral)

Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: A Center for International Blood and Marrow Transplant Research Study.

Citation

DeFilipp Z, Ancheta R, Liu Y, Hu Z-H, Gale RP, Snyder D, Schouten HC, Kalaycio M, Hildebrandt GC, Ustun C, Daly A, Ganguly S, Inamoto Y, Litzow M, Szer J, Savoie ML, Hossain N, Kharfan-Dabaja MA, Hamadani M, Reshef R, Bajel A, Schultz KR, Gadalla S, Gerds A, Liesveld J, Juckett MB, Kamble R, Hashmi S, Abdel-Azim H, Solh M, Bacher U, Lazarus H, Olsson R, Cahn J-Y, Grunwald MR, Savani BN, Yared J, Rowe JM, Cerny J, Chaudhri NA, Aljurf M, Beitinjaneh A, Seo S, Nishihori T, Hsu JW, Ramanathan M, Alyea E, Popat U, Sobecks R, Saber W.

Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2020, Mar 01: 26(3): 26(3):472-479. doi: 10.1016/j.bbmt.2019.10.017. Epub 2019, Oct 25. PMCID:PMC7358778.

PubMed

PMID: 31669399

Abstract